Dopamine Receptors

Total Page:16

File Type:pdf, Size:1020Kb

Dopamine Receptors Tocris ScientificDopamine Review Receptors Series Tocri-lu-2945 Dopamine Receptors Philip G. Strange1 and Kim Neve2 History 1School of Pharmacy, University of Reading, Whiteknights, It was not until the late 1950s that dopamine was recognized Reading, RG6 6AJ, UK, Email: [email protected] as a neurotransmitter in its own right, but the demonstration of its non-uniform distribution in the brain, distinct from the 2 VA Medical Center and Department of Behavioral Neuroscience, distribution of noradrenaline, suggested a specific functional Oregon Health & Science University, Portland, OR 97239, USA, role for dopamine.1 Interest in dopamine was intensified by Email: [email protected] the realization that dopamine had an important role in the Professor Philip Strange has worked on the structure and pathogenesis or drug treatment of certain neurological disorders, function of G protein-coupled receptors for many years. A major e.g. Parkinson’s disease and schizophrenia.2,3 This led to much focus of his work has been the receptors for the neurotransmitter research on the sites of action of dopamine and the dopamine dopamine, with particular emphasis on their role as targets receptors (Box 1). One milestone was the suggestion by Cools for drugs and understanding the mechanisms of agonism and and van Rossum, based on anatomical, electrophysiological inverse agonism at these receptors. and pharmacological studies, that there might be more than one kind of receptor for dopamine in the brain.4 Biochemical Professor Kim Neve has studied dopamine receptors for most studies on dopamine receptors in the 1970s based on second of his scientific career, with an emphasis on relating structural messenger assays (e.g. stimulation of cAMP production and features of the receptors to specific functions and assessing how ligand binding assays) supported the idea, and it was given a firm receptor responsiveness is altered by denervation or prolonged foundation by Kebabian and Calne in their 1979 review.5 They treatment with agonists. extended an earlier suggestion by Spano et al,6 and proposed that there were two classes of dopamine receptor, D1 and D2, with different biochemical and pharmacological properties, mediating different physiological functions. The properties of these two subtypes are summarized in Table 1. Selective agonists and antagonists exist to define the two subtypes in functional assays and some of these are shown in Table 1. Both the D1 and D2 subtypes are G protein-coupled receptors (GPCRs), yet different G proteins and effectors are involved in their signaling pathways (Figure 1, Table 1). Although there were some indications of further heterogeneity of these dopamine receptor subtypes in biochemical studies, it was not until the late 1980s that the true extent of this was revealed with the application of gene cloning techniques. These studies have shown that there are at least five dopamine receptors (D1– D5) that may be divided into two subfamilies whose properties 7,8 resemble the original D1 and D2 receptors. The D1-like receptor family, which comprises D1 and D5, corresponds to the original D1 receptors whilst the D2-like receptor family (D2, D3 and D4 Contents receptors) corresponds to the original D2 receptors. A selection History ...................................................................................................... 1 of the key properties of the receptor subtypes are summarized in Tables 2 and 3. Properties of the Dopamine Receptor Subtypes ................................. 2 Future Directions .................................................................................... 6 In subsequent discussion we refer to receptor subtypes defined from cloned genes as D , D , D , D , D , and where only the References .............................................................................................. 8 1 2 3 4 5 subfamily of receptor has been defined pharmacologically we Dopamine Compounds .......................................................................... 9 use the D1-like and D2-like nomenclature. tocris.com | 1 Tocris Scientific Review Series Properties of the Dopamine Receptor the membrane to form the ligand binding site (Figure 2); some information is available on the residues that make contact with Subtypes ligands.11,12 There is an intracellular carboxyl terminus, probably bearing a palmitoyl group, which may form a further link to the Common receptor properties membrane. The D1-like receptors have short third intracellular loops and long carboxyl terminal tails, whereas the D -like Analysis of the amino acid sequences of the dopamine receptor 2 subtypes has shown that significant homologies exist among receptors have long third intracellular loops and short carboxyl the subtypes, with the greatest being found between members terminal tails. This provides a structural basis for the division of either subfamily.7,8 Each receptor has been shown to contain of the receptors into two subfamilies but is also likely to have seven stretches of amino acids that are hydrophobic and long a functional significance, possibly related to the specificity of enough to span the membrane. It seems therefore that each of receptor/G protein interaction. the dopamine receptors conforms to the general structural model The third intracellular loop, termed ‘I3’, is important for the for a GPCR,9–11 with an extracellular amino terminus and seven interaction of the receptor and G protein. For the D2-like putative membrane spanning α-helices linked by intracellular receptors, variants of the subtypes exist based on this loop. For and extracellular protein loops (Figure 2). One or more potential example, there are short and long splice variants of the D2 and D3 sites for glycosylation are found on the amino terminus and receptors with the long forms having an insertion (29 amino acids second extracellular loop. The helices are bundled together in 13,14 for the long D2, D2L) in this loop. Polymorphic variants of the D2 receptor have been described with single amino acid changes 15 in I3. The D4 receptor is highly polymorphic in the human Figure 1 | Regulation of adenylyl cyclase by D and D dopamine 1 2 population with variants containing different length insertions receptors 16,17 in I3. In some cases, these D2-like receptor variants may Dopamine Dopamine Figure 2 | Schematic representation of a G protein-coupled D1-like receptor D2-like receptor dopamine receptor AC Extracellular space H N βγ + – βγ 2 Gαs Gαi/o Disulfide bond ATP E1 cAMP E2 E3 3 4 2 1 The diagram shows the effects of dopamine to stimulate or inhibit 5 α 6 7 adenylyl cyclase (AC) via the D1-like receptor and G protein G s or the D2-like receptor and G protein Gai/o, respectively. BoxBox 1: Dopamine 1: Dopamine receptor receptor products products Box 1: BoxDopamine 1: Dopamine receptor receptor products products Box 1 | Dopamine synthesis and metabolism I1 Palmitoyl NO O NO2 2 O P I2 group NO2 NO2O O O N O N H P O N O H N HO NH H H I3 HO NH2 2 HO HO NH2 NH2 OH HO OH HO OH OH HOOC HO HO OH OH Cytoplasm OH OH P P DopamineDopamine (3548) (3548) NPEC-caged-dopamineNPEC-caged-dopamine (3992) (3992) DopamineEndogenousDopamineEndogenous (3548)Dopamine dopamine (3548) dopamine (3548) NPEC-caged-dopamineNPEC-caged-dopamineCagedNPEC-caged-dopamineCaged version version of dopamine (3992)of (3992)dopamine (3992) EndogenousreceptorEndogenousEndogenousreceptor dopamine agonist agonist dopamine dopamine CagedCaged versionCaged version of version dopamine of dopamine of dopamine receptor agonistreceptorreceptor agonist agonist The diagram shows the seven helices bundled together in the membrane and the intra- (I1, I2, I3) and extracellular (E1, E2, E3) SO Me SO2Me 2 loops. The ligand binding site is contained in the cavity formed SO2Me SO2Me between the helices. There may be an eighth helix formed in the HO CO H H HO CO2H 2 H carboxyl terminus parallel to the membrane (not shown). There is HO HO CO2H CO2H H H N N also a disulfide bond between E2 and the top of helix 3. The NH NH2 HO 2 N N HO NH2 NH2 helices have been drawn parallel to one another for clarity but in HO HO fact there are kinks in the helices and they are not fully parallel. L-DOPAL-DOPA (3788)L-DOPA (3788) (3788) OSUOSU OSU6162 6162 6162(2599) (2599) (2599) I3 and the carboxyl terminus contain multiple sites for L-DOPADopamine (3788)L-DOPADopamineDopamine precursor (3788) precursor precursor OSU Dopamine6162DopamineOSU Dopamine(2599) 6162 stabilizer stabilizer (2599) stabilizer phosphorylation that are involved in regulation of receptor DopamineDopamine precursor precursor DopamineDopamine stabilizer stabilizer responsiveness and interactions with adapter proteins. 2 | tocris.com Dopamine Receptors 18,19 have differential abilities to couple to or activate G proteins, D1-like antagonist that is useful because it is structurally distinct and may also exhibit slightly different pharmacological from the benzazepines. Thioxanthines such as flupentixol and properties.16,20,21 Lines of mice have been developed in which the phenothiazines such as fluphenazine also show high affinity I3 insertion that produces the long D2 receptor variant (D2L) is but are not selective for D1-like over D2-like receptors. The deleted, resulting in the expression of only the short variant (D2S). development of the first 1D -like receptor agonist, SKF 38393, was Characterization of these mice suggests that the splice variants important for differentiating between activation of D1-like and are not fully interchangeable; some
Recommended publications
  • Sustained Release Tablet Comprising Pramipexole
    (19) & (11) EP 2 172 199 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 07.04.2010 Bulletin 2010/14 A61K 31/428 (2006.01) A61K 9/20 (2006.01) A61K 9/28 (2006.01) (21) Application number: 09178277.1 (22) Date of filing: 25.07.2003 (84) Designated Contracting States: • Lee, Ernest, J. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Kalamazoo, MI 49009 (US) HU IE IT LI LU MC NL PT RO SE SI SK TR • Martino, Alice, C. Kalamazoo, MI 49009 (US) (30) Priority: 25.07.2002 US 398427 P • Noack, Robert, M. 25.07.2002 US 398447 P Grand Rapids, MI 49506 (US) 28.08.2002 US 406609 P • Reo, Joseph, P. 18.06.2003 US 479387 P Kalamazoo, MI 49009 (US) • Skoug, Connie, J. (62) Document number(s) of the earlier application(s) in Portage, MI 49024 (US) accordance with Art. 76 EPC: 03771898.8 / 1 536 791 (74) Representative: Summers, Victoria Clare Pfizer Limited (71) Applicant: Pharmacia Corporation European Patent Department Peapack, NJ 07977 (US) Ramsgate Road Sandwich, Kent CT13 9NJ (GB) (72) Inventors: • Amidon, Gregory, E. Remarks: Portage, MI 49024 (US) This application was filed on 08-12-2009 as a • Ganorkar, Loksidh, D. divisional application to the application mentioned Kalamazoo, MI 49009 (US) under INID code 62. • Heimlich, John, M. Portage, MI 49002 (US) (54) Sustained release tablet comprising pramipexole (57) A sustained - release pharmaceutical composi- hydrophilic polymer and astarch having a tensile strength tion in a form of an orally deliverable tablet comprising of at least about 0.15kNcm -2 at a solid fraction represent- an active pharmaceutical agent having solubility not less ative of the tablet.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,486,621 B2 Luo Et Al
    USOO8486.621B2 (12) United States Patent (10) Patent No.: US 8,486,621 B2 Luo et al. (45) Date of Patent: Jul. 16, 2013 (54) NUCLEICACID-BASED MATRIXES 2005. O130180 A1 6/2005 Luo et al. 2006/0084607 A1 4/2006 Spirio et al. (75) Inventors: ity, N. (US); Soong Ho 2007/01482462007/0048759 A1 3/20076/2007 Luo et al. m, Ithaca, NY (US) 2008.0167454 A1 7, 2008 Luo et al. 2010, O136614 A1 6, 2010 Luo et al. (73) Assignee: Cornell Research Foundation, Inc., 2012/0022244 A1 1, 2012 Yin Ithaca, NY (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this WO WO 2004/057023 A1 T 2004 patent is extended or adjusted under 35 U.S.C. 154(b) by 808 days. OTHER PUBLICATIONS Lin et al. (J Biomech Eng. Feb. 2004;126(1):104-10).* (21) Appl. No.: 11/464,184 Li et al. (Nat Mater. Jan. 2004:3(1):38-42. Epub Dec. 21, 2003).* Ma et al. (Nucleic Acids Res. Dec. 22, 1986;14(24):9745-53).* (22) Filed: Aug. 11, 2006 Matsuura, et al. Nucleo-nanocages: designed ternary oligodeoxyribonucleotides spontaneously form nanosized DNA (65) Prior Publication Data cages. Chem Commun (Camb). 2003; (3):376-7. Li, et al. Multiplexed detection of pathogen DNA with DNA-based US 2007/01 17177 A1 May 24, 2007 fluorescence nanobarcodes. Nat Biotechnol. 2005; 23(7): 885-9. Lund, et al. Self-assembling a molecular pegboard. JAm ChemSoc. Related U.S. Application Data 2005; 127(50): 17606-7. (60) Provisional application No. 60/722,032, filed on Sep.
    [Show full text]
  • Parkinson's Disease Current Awareness Bulletin
    Parkinson’s Disease Current Awareness Bulletin February 2018 A number of other bulletins are also available – please contact the Academy Library for further details If you would like to receive these bulletins on a regular basis please contact the library. For any references where there is a link to the full text please use your NHS Athens username & password to access If you would like any of the full references from those that do not have links we will source them for you. Contact us: Academy Library 824897/98 Email: [email protected] Title: Motor imagery training with augmented cues of motor learning on cognitive functions in patients with Parkinsonism Citation: International Journal of Therapy and Rehabilitation; 2018; vol. 25 (no. 1); p. 13 Author(s): Lama Saad El Din Mahmoud; Nawal Abd EL Raouf Abu Shady; Ehab Shaker Hafez Objective: Patients with Parkinsonism demonstrate impairments in cognitive functions, such as deficit in attention, planning, and working memory. The objective was to investigate the effect of motor imagery training with augmented cues of motor learning on cognitive functions in patients with Parkinsonism. Methods: A total of 30 patients from both sexes participated in this study. All of the patients had been diagnosed as idiopathic Parkinson patients experiencing cognitive dysfunction. The patients were randomly divided into two equal groups: the study group (n=15) received motor imagery training with augmented cues of motor learning and the specifically designed intervention. The control group (n=15) received conventional treatment (cognitive remediation therapy). The treatment took place three times a week for 6 weeks (18 sessions).
    [Show full text]
  • Abstract Introduction Objectives Methods
    ABSTRACT Table 3. Summary of Drug Interaction Evaluation Lack of Significant Drug Interactions for Sumanirole in Phase II Studies Using PURPOSE: Sumanirole is a highly D -selective dopamine 2 Number of Number of receptor agonist that is in development for the treatment of Population Pharmacokinetic Methods Subjects Observations Parkinson's disease (PD). Metabolism of sumanirole and in Change on With vitro data indicate that clinically significant pharmacokinetic in Mean % of the Univariate Concomit- Concomit- (PK) drug-drug interactions are unlikely. This was further Joel S. Owen, PhD1, Kathryn Liolios, MA1, Gwyn A. D'Souza, PhD2, Barbara J. Carel, MS3 Drug CL/F SEM P Value ant Drug ant Drug investigated using population pharmacokinetic (PPK) 1 2 Amantadine 0.434 440.1 0.629 71 407 methodology. Cognigen Corporation, Buffalo, NY, USA; Pharmacia Corporation, High Wycombe, UK; 3Pharmacia Corporation, Kalamazoo, MI, USA Aspirin 0.601 196.3 0.349 77 496 METHODS: Data were obtained from 2 double-blind, placebo- β-Blockers* 2.22 154.1 0.066 22 144 controlled trials of sumanirole alone in early PD and sumani- role with levodopa in advanced PD. Patients received twice- Hypotensive † daily extended-release oral sumanirole doses ranging from 2 agents 0.0943 1124.1 0.882 128 815 to 48 mg/d. A one-compartment PPK model, with creatinine Levodopa‡ 0.907 100.0 0.281 111 200 clearance (CrCL) and gender as covariates of clearance Organic anion (CL/F), was used in NONMEM® to characterize the influence METHODS Figure 1. Sumanirole concentrations versus time transport of concomitantly administered drugs on sumanirole PK.
    [Show full text]
  • Dopamine Agonists for the Treatment of Restless Legs Syndrome (Review)
    Dopamine agonists for the treatment of restless legs syndrome (Review) Scholz H, Trenkwalder C, Kohnen R, Kriston L, Riemann D, Hornyak M This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2011, Issue 5 http://www.thecochranelibrary.com Dopamine agonists for the treatment of restless legs syndrome (Review) Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 2 BACKGROUND .................................... 6 OBJECTIVES ..................................... 8 METHODS ...................................... 8 Figure1. ..................................... 10 Figure2. ..................................... 11 RESULTS....................................... 13 Figure3. ..................................... 16 Figure4. ..................................... 18 Figure5. ..................................... 20 Figure6. ..................................... 22 Figure7. ..................................... 24 Figure8. ..................................... 26 Figure9. ..................................... 28 Figure10. ..................................... 30 ADDITIONALSUMMARYOFFINDINGS . 31 DISCUSSION ..................................... 36 AUTHORS’CONCLUSIONS . 38 ACKNOWLEDGEMENTS . 38 REFERENCES ..................................... 39 CHARACTERISTICSOFSTUDIES
    [Show full text]
  • Methods for Treatment of Parkinson's Disease
    (19) TZZ ZZ _T (11) EP 2 070 526 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/16 (2006.01) A61P 25/16 (2006.01) 26.02.2014 Bulletin 2014/09 (21) Application number: 09154864.4 (22) Date of filing: 08.04.2004 (54) Methods for treatment of Parkinson’s disease Verfahren zur Behandlung von Parkinson-Krankheit Procedes de traitment de la maladie de Parkinson (84) Designated Contracting States: • Benatti, Luca AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 20091 BRESSO (MI) (IT) HU IE IT LI LU MC NL PL PT RO SE SI SK TR (74) Representative: Minoja, Fabrizio (30) Priority: 11.04.2003 US 462205 P Bianchetti Bracco Minoja S.r.l. Via Plinio, 63 (43) Date of publication of application: 20129 Milano (IT) 17.06.2009 Bulletin 2009/25 (56) References cited: (62) Document number(s) of the earlier application(s) in EP-A- 0 400 495 US-A- 5 391 577 accordance with Art. 76 EPC: US-A- 5 945 454 04726590.5 / 1 613 296 • ANONYMOUS: "Newron Releases Positive (73) Proprietor: Newron Pharmaceuticals S.p.A. Preliminary Phase II Data for Salfinamide in 20091 Bresso (MI) (IT) Parkinson’s Disease" PRESS RELEASE OF 03.01.03, [Online] XP002290820 Retrieved from (72) Inventors: the Internet: URL:http://www.newron.com/ • Ruggero, Fariello press.asp?Action =news&intNewsID=1> 20091 BRESSO (MI) (IT) [retrieved on 2004-08-01] • Cattaneo, Carlo • BRUSA ET AL: "Pramipexole in comparison to L- 20091 BRESSO (MI) (IT) Dopa; a neuropsychological study.", • Salvati Patricia J.NEURAL.TRANSM., vol.
    [Show full text]
  • Neurotransmission Product Guide | Edition 1
    Neurotransmission Product Guide | Edition 1 Delphinium Delphinium A source of Methyllycaconitine Contents by Research Area: • Dopaminergic Transmission • Glutamatergic Transmission • Opioid Peptide Transmission • Serotonergic Transmission • Chemogenetics Tocris Product Guide Series Neurotransmission Research Contents Page Principles of Neurotransmission 3 Dopaminergic Transmission 5 Glutamatergic Transmission 6 Opioid Peptide Transmission 8 Serotonergic Transmission 10 Chemogenetics in Neurotransmission Research 12 Depression 14 Addiction 18 Epilepsy 20 List of Acronyms 22 Neurotransmission Research Products 23 Featured Publications and Further Reading 34 Introduction Neurotransmission, or synaptic transmission, refers to the passage of signals from one neuron to another, allowing the spread of information via the propagation of action potentials. This process is the basis of communication between neurons within, and between, the peripheral and central nervous systems, and is vital for memory and cognition, muscle contraction and co-ordination of organ function. The following guide outlines the principles of dopaminergic, opioid, glutamatergic and serotonergic transmission, as well as providing a brief outline of how neurotransmission can be investigated in a range of neurological disorders. Included in this guide are key products for the study of neurotransmission, targeting different neurotransmitter systems. The use of small molecules to interrogate neuronal circuits has led to a better understanding of the under- lying mechanisms of disease states associated with neurotransmission, and has highlighted new avenues for treat- ment. Tocris provides an innovative range of high performance life science reagents for use in neurotransmission research, equipping researchers with the latest tools to investigate neuronal network signaling in health and disease. A selection of relevant products can be found on pages 23-33.
    [Show full text]
  • Pharmacotherapy for Stimulant Use Disorders: a Systematic Review
    4 D epartment of Veterans Affairs Health Services Research & Development Service Evidence-based Synthesis Program Pharmacotherapy for Stimulant Use Disorders: A Systematic Review August 2018 Prepared for: Investigators: Department of Veterans Affairs Principal Investigator: Veterans Health Administration Brian Chan, MD, MPH Quality Enhancement Research Initiative Co-Investigators: Health Services Research & Development Service Karli Kondo, PhD, MA Washington, DC 20420 Chelsea Ayers, BA Prepared by: Michele Freeman, MPH Jessica Montgomery, MPH Evidence-based Synthesis Program (ESP) Robin Paynter, MLIS Portland VA Health Care System Devan Kansagara, MD, MCR Portland, OR Devan Kansagara, MD, MCR, Director 4 Pharmacotherapy for Stimulant Use Disorders Evidence-based Synthesis Program PREFACE The VA Evidence-based Synthesis Program (ESP) was established in 2007 to provide timely and accurate syntheses of targeted healthcare topics of particular importance to clinicians, managers, and policymakers as they work to improve the health and healthcare of Veterans. QUERI provides funding for 4 ESP Centers, and each Center has an active University affiliation. Center Directors are recognized leaders in the field of evidence synthesis with close ties to the AHRQ Evidence-based Practice Centers. The ESP is governed by a Steering Committee comprised of participants from VHA Policy, Program, and Operations Offices, VISN leadership, field-based investigators, and others as designated appropriate by QUERI/HSR&D. The ESP Centers generate evidence syntheses on important clinical practice topics. These reports help: · Develop clinical policies informed by evidence; · Implement effective services to improve patient outcomes and to support VA clinical practice guidelines and performance measures; and · Set the direction for future research to address gaps in clinical knowledge.
    [Show full text]
  • Behavioral Pharmacology of Dopamine D2 and D3 Receptor Agonists and Antagonists in Rats
    Behavioral Pharmacology of Dopamine D2 and D3 Receptor Agonists and Antagonists in Rats. by Gregory T. Collins A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Pharmacology) in The University of Michigan 2008 Doctoral Committee: Professor James H. Woods, Chair Professor Margaret E. Gnegy Professor Shaomeng Wang Assistant Professor Roger K. Sunahara © Gregory T. Collins 2008 DEDICATION This thesis is dedicated to my parents, Thomas and Shirley Collins, without whom none of this would have been possible. Your continual support and encouragement throughout all of my endeavors has meant more than you will ever know. Thank you. ii ACKNOWLEDGMENTS First and foremost, I would like to thank my mentor, James Woods. You have been an exceptional mentor to me; I have learned more than I could have ever hoped. It has been a pleasure to work with someone who is so passionate and knowledgable, someone who has not only continued to challenge me, but has also provided an outstanding environment in which to study behavioral pharmacolgy. I truly feel lucky to have been able to learn from you. Of course, I also have to thank Gail Winger who has been a second mentor to me throughout the years. The support, encouragement, guidance, and patience that the two of you have provided has made for an exceptional experience. Thank you. I would also like to thank my committee, James Woods, Roger Sunahara, Peggy Gnegy and Shaomeng Wang. I am grateful to have been able to work with and learn from all of you over the years.
    [Show full text]
  • Download Program
    11TH ANNUAL BEHAVIOR, BIOLOGY, and CHEMISTRY: Translational Research in Addiction San Antonio, Texas | Omni Colonnade | 2-3 March 2019 BBC Publications BBC 2011 Stockton Jr SD and Devi LA (2012) Functional relevance of μ–δ opioid receptor heteromerization: A Role in novel signaling and implications for the treatment of addiction disorders: From a symposium on new concepts in mu-opioid pharmacology. Drug and Alcohol Dependence 121, 167-72. PMC3288266 Traynor J (2012) μ-Opioid receptors and regulators of G protein signaling (RGS) proteins: From a symposium on new concepts in mu-opioid pharmacology. Drug and Alcohol Dependence 121, 173-80. PMC3288798 Lamb K, Tidgewell K, Simpson DS, Bohn LM and Prisinzano TE (2012) Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: New concepts in mu opioid receptor pharmacology: From a symposium on new concepts in mu-opioid pharmacology. Drug and Alcohol Dependence 121, 181-88. PMC3288203 Whistler JL (2012) Examining the role of mu opioid receptor endocytosis in the beneficial and side-effects of prolonged opioid use: From a symposium on new concepts in mu-opioid pharmacology. Drug and Alcohol Dependence 121, 189-204. PMC4224378 BBC 2012 Zorrilla EP, Heilig M, de Wit H and Shaham Y (2013) Behavioral, biological, and chemical perspectives on targeting CRF1 receptor antagonists to treat alcoholism. Drug and Alcohol Dependence 128, 175-86. PMC3596012 BBC 2013 De Biasi M, McLaughlin I, Perez EE, Crooks PA, Dwoskin LP, Bardo MT, Pentel PR and Hatsukami D (2014) Scientific overview: 2013 BBC plenary symposium on tobacco addiction. Drug and Alcohol Dependence 141, 107-17.
    [Show full text]
  • Comparison of the Efficacy of Different Drugs on Non-Motor Symptoms of Parkinson’S Disease: a Network Meta- Analysis
    Cellular Physiology Cell Physiol Biochem 2018;45:119-130 DOI: 10.1159/00048625210.1159/000486252 © 2018 The Author(s).© 2018 Published The Author(s) by S. Karger AG, Basel Published online: online: January January 15, 15, 2018 2018 www.karger.com/cpbPublished by S. Karger AG, Basel 119 and Biochemistry www.karger.com/cpb Li et al.: Efficacy of Different Drugs on PD Accepted: October 09, 2017 This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Interna- tional License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Original Paper Comparison of the Efficacy of Different Drugs on Non-Motor Symptoms of Parkinson’s Disease: a Network Meta- Analysis Bao-Dong Lia Jing-Jun Cuia Jia Songa Ce Qia Pei-Feng Maa Ya-Rong Wanga Jing Baib, aDepartment of Neurology, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, Cangzhou, bDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China Key Words Parkinson’s disease • Non-motor symptoms • UPDRS • Apomorphine • Efficacy • Drug therapy • Randomized controlled trials • Bayesian network model Abstract Background/Aims: A network meta-analysis is used to compare the efficacy of ropinirole, rasagiline, rotigotine, entacapone, apomorphine, pramipexole, sumanirole, bromocriptine, piribedil and levodopa, with placebo as a control, for non-motor symptoms in Parkinson’s disease (PD). Methods: PubMed, Embase and the Cochrane Library were searched from their establishment dates up to January 2017 for randomized controlled trials (RCTs) investigating the efficacy of the above ten drugs on the non-motor symptoms of PD.
    [Show full text]
  • Early Life Stress, Depression and Parkinson's Disease
    Dallé and Mabandla Molecular Brain (2018) 11:18 https://doi.org/10.1186/s13041-018-0356-9 REVIEW Open Access Early Life Stress, Depression And Parkinson’s Disease: A New Approach Ernest Dallé1* and Musa V. Mabandla2 Abstract This review aims to shed light on the relationship that involves exposure to early life stress, depression and Parkinson’s disease (PD). A systematic literature search was conducted in Pubmed, MEDLINE, EBSCOHost and Google Scholar and relevant data were submitted to a meta-analysis. Early life stress may contribute to the development of depression and patients with depression are at risk of developing PD later in life. Depression is a common non-motor symptom preceding motor symptoms in PD. Stimulation of regions contiguous to the substantia nigra as well as dopamine (DA) agonists have been shown to be able to attenuate depression. Therefore, since PD causes depletion of dopaminergic neurons in the substantia nigra, depression, rather than being just a simple mood disorder, may be part of the pathophysiological process that leads to PD. It is plausible that the mesocortical and mesolimbic dopaminergic pathways that mediate mood, emotion, and/or cognitive function may also play a key role in depression associated with PD. Here, we propose that a medication designed to address a deficiency in serotonin is more likely to influence motor symptoms of PD associated with depression. This review highlights the effects of an antidepressant, Fluvoxamine maleate, in an animal model that combines depressive-like symptoms and Parkinsonism. Keywords: Early stress, Depression, Dopamine, Fluvoxamine maleate, Parkinson’s disease Introduction which stimulates the release of adrenocorticotropic hor- Stress is defined as a sudden inconsistent physical, physio- mone (ACTH) from the anterior pituitary gland, which in logical and social environmental change experienced by turn, facilitates the release of cortisol/corticosterone re- an organism [1–3].
    [Show full text]